SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Stroke
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter H. Proctor who wrote (40)3/27/2004 3:25:35 PM
From: Miljenko Zuanic  Read Replies (1) of 70
 
Peter,

Please tell as where is word *systemic* incorporated in your 502 patent claims?

While you cited reference (review article) as source of the your contribution to SOD/antioxidants rule in variety of diseases, I do not see strong claims that you may claim IP on PBN-disulfate derivative and its use in stroke or other neuro-degenerative diseases.

"PBN can also be useful by topical, oral or parental administration in ameliorating the rate of protein oxidation, DNA scission, cell viability loss, and the like in the tissue of internal organs such as the heart and brain...."

Here PBN does not cover PBN-derivative that makes it systemic possible.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News